Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Serum amyloid A as an early predictor of severity in COVID-19

Serum amyloid A (SAA) is a well-established inflammation marker, in particular for viral infections. During the first SARS-CoV-1 epidemic in 2004 and again during the SARS-CoV-2 pandemic, SAA has proven to be the best inflammation marker to predict and monitor COVID-19 severity and disease progression. In this webinar, Dr. Pouw reintroduces SAA and summarizes its utility in COVID-19 disease management.

Nadine Pouw, Franciscus, Gasthuis & Vlietland

Dr. Nadine Pouw
Franciscus, Gasthuis & Vlietland
Netherlands